Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View Item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.

Thumbnail
View/Open
Supporting information (63.31Kb)
Publication Date
2017-01
ICR Author
Jones, Robin
Marsden,
Baker, Lauren
Author
Higham, CS
Steinberg, SM
Dombi, E
Perry, A
Helman, LJ
Schuetze, SM
Ludwig, JA
Staddon, A
Milhem, MM
Rushing, D
Jones, RL
Livingston, M
Goldman, S
Moertel, C
Wagner, L
Janhofer, D
Annunziata, CM
Reinke, D
Long, L
Viskochil, D
Baker, L
Widemann, BC
Type
Journal Article
Metadata
Show full item record
Abstract
Background:Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant peripheral nerve sheath tumors (MPNST) has been reported. Methods:We evaluated the objective response (OR) rate of patients with AJCC Stage III/IV chemotherapy-naive NF1 MPNST versus sporadic MPNST after 4 cycles of neoadjuvant chemotherapy, 2 cycles of ifosfamide/doxorubicin, and 2 cycles of ifosfamide/etoposide. A Simon optimal two-stage design was used (target response rate 40%). Results:34 NF1 (median age 33 years) and 14 sporadic (median age 40 years) MPNST patients enrolled. Five of 28 (17.9%) evaluable NF1 MPNST patients had a partial response (PR), as did 4 of 9 (44.4%) patients with sporadic MPNST. Stable disease (SD) was achieved in 22 NF1 and 4 sporadic MPNST patients. In both strata, results in the initial stages met criteria for expansion of enrollment. Only 1 additional PR was observed in the expanded NF1 stratum. Enrollment was slower than expected and the trial closed before full accrual. Conclusions:This trial was not powered to detect differences in response rates between NF1 and sporadic MPNST. While the OR rate was lower in NF1 compared to sporadic MPNST, qualitative responses were similar, and disease stabilization was achieved in most patients.
URL
https://repository.icr.ac.uk/handle/internal/1263
Collections
  • Clinical Studies
  • Radiotherapy and Imaging
Licenseref URL
https://creativecommons.org/licenses/by/4.0
Version of record
10.1155/2017/8685638
Research team
Sarcoma Clinical Trials (R Jones)
Magnetic Resonance
Language
eng
Date accepted
2017-08-10
License start date
2017-01
Citation
Sarcoma, 2017, 2017 pp. 8685638 - ?

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.